8JMI
 
 | |
8JMA
 
 | |
8JME
 
 | |
8JMH
 
 | |
3U4U
 
 | Casein kinase 2 in complex with AZ-Inhibitor | Descriptor: | 3-{5-(acetylamino)-3-[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]-1H-indol-1-yl}propanoic acid, CHLORIDE ION, Casein kinase II subunit alpha | Authors: | Larsen, N.A, Dowling, J. | Deposit date: | 2011-10-10 | Release date: | 2012-08-22 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization. ACS Med Chem Lett, 3, 2012
|
|
9FKY
 
 | Discovery of a Series of Covalent, Cell Active Bfl-1 Inhibitors | Descriptor: | Bcl-2-related protein A1, ~{N}-[4-[(1~{R},3~{R})-3-azanylcyclopentyl]oxyphenyl]-~{N}-[(1~{S})-1-[3-cyano-4-(trifluoromethyl)phenyl]ethyl]propanamide | Authors: | Hargreaves, D. | Deposit date: | 2024-06-04 | Release date: | 2024-10-02 | Last modified: | 2024-10-09 | Method: | X-RAY DIFFRACTION (1.557 Å) | Cite: | Structure-Based Optimization of a Series of Covalent, Cell Active Bfl-1 Inhibitors. J.Med.Chem., 67, 2024
|
|
9FKZ
 
 | Discovery of a Series of Covalent, Cell Active Bfl-1 Inhibitors | Descriptor: | Bcl-2-related protein A1, ~{N}-[4-[(1~{R},3~{R})-3-azanylcyclopentyl]oxyphenyl]-~{N}-[(4-chlorophenyl)methyl]prop-2-enamide | Authors: | Hargreaves, D. | Deposit date: | 2024-06-04 | Release date: | 2024-10-02 | Last modified: | 2024-10-09 | Method: | X-RAY DIFFRACTION (1.684 Å) | Cite: | Structure-Based Optimization of a Series of Covalent, Cell Active Bfl-1 Inhibitors. J.Med.Chem., 67, 2024
|
|
9GIR
 
 | BFL1 covalently bound to inhibitor compound 39 | Descriptor: | Bcl-2-related protein A1, ~{N}-[4-[(1~{R},3~{R})-3-[[(3~{R})-1,1-bis(oxidanylidene)thiolan-3-yl]carbamoylamino]cyclopentyl]oxy-3-chloranyl-phenyl]-~{N}-[(1~{S})-1-(4-chlorophenyl)ethyl]propanamide | Authors: | Cottee, M.A. | Deposit date: | 2024-08-19 | Release date: | 2024-12-18 | Last modified: | 2025-01-08 | Method: | X-RAY DIFFRACTION (1.075 Å) | Cite: | Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors. J.Med.Chem., 67, 2024
|
|
9GIQ
 
 | BFL1 covalently bound to inhibitor compound 13 | Descriptor: | (2S,3S)-butane-2,3-diol, Bcl-2-related protein A1, ~{N}-[4-[(1~{R},3~{R})-3-azanylcyclopentyl]oxyphenyl]-~{N}-[(1~{S})-1-(4-chlorophenyl)-3-methyl-3-oxidanyl-butyl]propanamide | Authors: | Cottee, M.A. | Deposit date: | 2024-08-19 | Release date: | 2024-12-18 | Last modified: | 2025-01-08 | Method: | X-RAY DIFFRACTION (1.421 Å) | Cite: | Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors. J.Med.Chem., 67, 2024
|
|
9GIP
 
 | BFL1 covalently bound to inhibitor compound 7 | Descriptor: | Bcl-2-related protein A1, ~{N}-[4-[(1~{R},3~{R})-3-azanylcyclopentyl]oxyphenyl]-~{N}-[(1~{S})-1-(4-chlorophenyl)ethyl]propanamide | Authors: | Hargreaves, D, Cottee, M.A. | Deposit date: | 2024-08-19 | Release date: | 2024-12-18 | Last modified: | 2025-01-08 | Method: | X-RAY DIFFRACTION (1.463 Å) | Cite: | Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors. J.Med.Chem., 67, 2024
|
|
9GIT
 
 | BFL1 covalently bound to inhibitor compound 43 | Descriptor: | (3~{S})-3-[[4-[(1~{R},3~{R})-3-[[(3~{R})-1,1-bis(oxidanylidene)thiolan-3-yl]carbamoylamino]cyclopentyl]oxy-3-fluoranyl-phenyl]-propanoyl-amino]-3-(4-chlorophenyl)propanamide, Bcl-2-related protein A1 | Authors: | Cottee, M.A. | Deposit date: | 2024-08-19 | Release date: | 2024-12-18 | Last modified: | 2025-01-08 | Method: | X-RAY DIFFRACTION (1.145 Å) | Cite: | Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors. J.Med.Chem., 67, 2024
|
|
9GIS
 
 | BFL1 covalently bound to inhibitor compound 17 | Descriptor: | Bcl-2-related protein A1, ~{N}-[(1~{S})-1-(4-chlorophenyl)ethyl]-~{N}-[4-[(1~{R},3~{R})-3-[[(3~{S})-pyrrolidin-3-yl]carbamoylamino]cyclopentyl]oxyphenyl]propanamide | Authors: | Cottee, M.A. | Deposit date: | 2024-08-19 | Release date: | 2024-12-18 | Last modified: | 2025-01-08 | Method: | X-RAY DIFFRACTION (1.387 Å) | Cite: | Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors. J.Med.Chem., 67, 2024
|
|
9GIO
 
 | |
9FL0
 
 | Discovery of a Series of Covalent, Cell Active Bfl-1 Inhibitors | Descriptor: | Bcl-2-related protein A1, ~{N}-[(4-chlorophenyl)methyl]-~{N}-(4-fluorophenyl)prop-2-enamide | Authors: | Hargreaves, D. | Deposit date: | 2024-06-04 | Release date: | 2024-10-02 | Last modified: | 2024-10-09 | Method: | X-RAY DIFFRACTION (1.94 Å) | Cite: | Structure-Based Optimization of a Series of Covalent, Cell Active Bfl-1 Inhibitors. J.Med.Chem., 67, 2024
|
|
9J38
 
 | human KCNQ5-CaM in apo state | Descriptor: | Calmodulin-1, Potassium voltage-gated channel subfamily KQT member 5 | Authors: | Yang, Z, Guo, J. | Deposit date: | 2024-08-08 | Release date: | 2025-04-16 | Last modified: | 2025-05-14 | Method: | ELECTRON MICROSCOPY (2.4 Å) | Cite: | Phosphatidylinositol 4,5-bisphosphate activation mechanism of human KCNQ5. Proc.Natl.Acad.Sci.USA, 122, 2025
|
|
6LG2
 
 | VanR bound to Vanillate | Descriptor: | 4-HYDROXY-3-METHOXYBENZOATE, Predicted transcriptional regulators | Authors: | He, Y, Bharath, S.R, Song, H. | Deposit date: | 2019-12-04 | Release date: | 2020-02-12 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Developing a highly efficient hydroxytyrosol whole-cell catalyst by de-bottlenecking rate-limiting steps. Nat Commun, 11, 2020
|
|
7BV7
 
 | INTS3 complexed with INTS6 | Descriptor: | Integrator complex subunit 3, Integrator complex subunit 6 | Authors: | Jia, Y, Bharath, S.R, Song, H. | Deposit date: | 2020-04-09 | Release date: | 2021-07-14 | Last modified: | 2024-05-29 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Crystal structure of the INTS3/INTS6 complex reveals the functional importance of INTS3 dimerization in DSB repair. Cell Discov, 7, 2021
|
|